难治性高血压影响12%的高血压患者。SymplicityHTN-2随机对照试验结果显示,经皮导管射频消融去肾交感神经术(renal denervation,RDN)可使基线收缩压(178±18)mmHg(1mmHg=0.133kPa)降低(32±23)mmHg。该研究旨在评估难治性高血压患者行RDN的成本效益和长期临床疗效。方法 :应用状态转换模型预测RDN和规范治疗对10年以及终身 Refractory hypertension affects 12% of hypertensive patients. SymplicityHTN-2 randomized controlled trial showed that the baseline systolic pressure (178 ± 18) mmHg (1 mmHg = 0.133 kPa) was reduced by (32 ± 23) mmHg by percutaneous catheter ablation of renal denervation (RDN). The aim of the study was to evaluate the cost-effectiveness and long-term clinical efficacy of RDN in patients with refractory hypertension. Methods: Apply the state transition model to predict RDN and standardize treatment for 10 years and for life